Journal
NANOTECHNOLOGY REVIEWS
Volume 2, Issue 3, Pages 241-257Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/ntrev-2012-0084
Keywords
biodistribution; blood-brain barrier; brain; drug delivery; nanoparticles
Categories
Funding
- LSU AgCenter Biotechnology Interdisciplinary Team (BAIT) Program
- Pennington Biomedical Research Center/Pennington Biomedical Research Center/Reilly Family Foundation (RFF)
- EPA-G2010-STAR-N2 Food Matrices Award [2010-05269]
Ask authors/readers for more resources
The blood-brain barrier (BBB), which protects the central nervous system (CNS) from unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many therapeutic agents such as hydrophilic and macromolecular drugs cannot overcome the BBB. One promising solution is the employment of polymeric nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the past few years, significant breakthroughs have been made in developing suitable PLGA and poly (lactic acid) (PLA) NPs for drug delivery across the BBB. Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs are reviewed in this paper. Both in vitro and in vivo studies are included. In these papers, enhanced cellular uptake and therapeutic efficacy of drugs delivered with modified PLGA/PLA NPs compared with free drugs or drugs delivered by unmodified PLGA/PLA NPs were shown; no significant in vitro cytotoxicity was observed for PLGA/PLA NPs. Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake (<1 %), which indirectly confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available